

COURSE FACULTY, IAS–USA STAFF, BOARD OF DIRECTORS, AND VIRAL HEPATITIS ADVISORY BOARD FINANCIAL RELATIONSHIPS WITH COMMERCIAL ENTITIES

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, IAS–USA Board members, Viral Hepatitis Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the previous 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity. The **ACCME defines a commercial interest** as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The **ACCME** does not consider providers of clinical service directly to patients to be **commercial interests** – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.” Below are the financial interests that faculty members of this course have had within the past 12 months as of the date listed. View the [Faculty Financial Disclosure Policy](#).

NEW YORK, NEW YORK—MARCH 18, 2019

Course Chairs	
Gerald H. Friedland, MD Professor of Medicine, Epidemiology, and Public Health Yale University New Haven, Connecticut	<i>Dr Friedland has no relevant financial affiliations to disclose. (Updated 03/08/18)</i>
Paul A. Volberding, MD Professor of Medicine University of California San Francisco San Francisco, California	<i>Dr Volberding has served on data and safety monitoring boards for Merck. (Updated 10/09/18)</i>
Speakers	
Kristine M. Erlandson, MD, MS Associate Professor of Medicine University of Colorado Aurora, Colorado	<i>Dr Erlandson has received grants paid to her institution from Merck & Co, Inc, and served as a consultant to Gilead Sciences, Inc, and ViiV Healthcare. (Updated 03/14/19)</i>
Rajesh T. Gandhi, MD Professor of Medicine Harvard Medical School Boston, Massachusetts	<i>Dr Gandhi has served as a consultant or advisor to Merck and Gilead Sciences, Inc, and received educational and research grants to his institution from ViiV Healthcare, Janssen Therapeutics, Theratechnologies, and Gilead Sciences, Inc. (Updated 03/15/19)</i>
Roy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Chief, Division of Infectious Diseases Weill Cornell Medicine New York, New York	<i>Dr Gulick has no relevant financial affiliations to disclose. (Updated 02/18/19)</i>
Sharon A. Nachman, MD Professor of Pediatrics Associate Dean for Research SUNY Stony Brook University Stony Brook, New York	<i>Dr Nachman has no relevant financial affiliations to disclose. (Updated 03/15/19)</i>
Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham, Alabama	<i>Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc and ViiV Healthcare. (Updated 03/12/19)</i>
Magdalena E. Sobieszczyk, MD, MPH Associate Professor of Medicine Columbia University New York, New York	<i>Dr Sobieszczyk has no relevant financial affiliations to disclose. (Updated 03/15/19)</i>
IAS–USA CME Planner and Reviewer	
Donna M. Jacobsen Executive Director	<i>Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 03/13/19)</i>
IAS–USA Board of Directors	
The nonstaff members of the IAS–USA Board of Directors are not compensated for their roles in governing and overseeing the IAS–USA. Please see https://iasusa.org/about/ias-usa-board-of-directors/ for information about board members and a link to up-to-date financial disclosure information.	
IAS–USA Viral Hepatitis Advisory Board	
The members of the IAS–USA Viral Hepatitis Advisory Board are not compensated for their roles in governing and overseeing the IAS–USA viral hepatitis educational efforts. Please see https://iasusa.org/activities/live-courses/hepatitis-c-virus-courses/viral-hepatitis-advisory-board/ for information about the financial disclosures for the IAS–USA Viral Hepatitis Advisory Board.	